Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis
Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis
复制标题
DOI：
10.1182/blood.v99.1.381
复制
发表时间：
2002-01-01
期刊：
影响因子：
20.3
通讯作者：
Linkesch, W
中科院分区：
文献类型：
--
作者：
Beham-Schmid, C;Apfelbeck, U;Linkesch, W
对bcr-abl阳性慢性粒细胞白血病(CML)患者在应用酪氨酸激酶抑制剂STI571治疗过程中的骨髓形态变化进行了研究。对23例CML患者在STI571治疗前、治疗后6周和3个月(Glivec，Novartis，巴塞尔，瑞士)的骨髓环钻活检标本进行了形态学和形态计量学检查。治疗期间骨髓改变显示红细胞数量正常化，粒细胞明显减少，巨核细胞显著减少，出现正常大小的形态。此外，在初发纤维化的患者中，骨髓纤维化显著消退(P
Morphologic bone marrow changes in patients with BCR-ABL-positive chronic myelogenous leukemia (CML) were investigated during treatment with the tyrosine kinase inhibitor STI571. Bone marrow trephine biopsy specimens from 23 pretreated patients with CML were examined morphologically and by morphometry before and 6 weeks and 3 months after the initiation of STI571 therapy (Glivec, Novartis, Basel, Switzerland). Bone marrow changes during treatment showed ar quantitative normalization of erythropoiesis, a marked reduction of granulopoiesis, and a significant decrease in megakaryocytes with the reappearance of normal-sized forms. Furthermore, a significant regression of bone marrow fibrosis was observed in patients with initial fibrosis (P